Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 271-280 of 421 for breast cancer

Edit search filters
  1. A Study Evaluating Safety And Efficacy Of The Addition Of ABT-888 Plus Carboplatin Versus The Addition Of Carboplatin To Standard Chemotherapy Versus Standard Chemotherapy In Subjects With Early Stage Triple Negative Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  2. A Study To Evaluate Tucatinib And Trastuzumab In Solid Tumors With HER2 Alterations

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. Olaparib And Onalespib In Treating Patients With Solid Tumors That Are Metastatic Or Cannot Be Removed By Surgery Or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, Or Triple-Negative Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study To Evaluate The Safety And Effectiveness Of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant As Treatment For Locally Advanced (Inoperable) Or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer

    Jacksonville, FL, Rochester, MN

  5. A Study Of Pembrolizumab (MK-3475) Versus Placebo In Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy In The Treatment Of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

    Rochester, MN

  6. Study Of Radium-223 Dichloride Versus Placebo And Hormonal Treatment As Background Therapy In Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

    Rochester, MN

  7. Study Of Radium-223 Dichloride Versus Placebo And Treatment With Exemestane / Everolimus In Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

    Rochester, MN

  8. A Study Of Accelerated 3 Fraction Photon,Proton Or Brachytherapy For Early Invasive And Noninvasive Breast Ca

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study To Compare Venetoclax With Fulvestrant Vs. Fulvestrant Alone In Women With Locally Advanced Or Metastatic HER2-negative Cancer Who Have Progressed Or Recurred On A CDK4/6 Inhibitor

    Scottsdale/Phoenix, AZ

  10. Assessing Breast Cancer Risk Among Hispanic Women In Maricopa County

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer